DS 1647

Drug Profile

DS 1647

Alternative Names: DS-1647; G47 delta oncolytic virus therapy; G47 delta oncolytic virus therapy - Daiichi Sankyo/University of Tokyo; G47 Δ oncolytic virus therapy; G47-delta; G47Δ oncolytic virus therapy - Daiichi Sankyo/University of Tokyo

Latest Information Update: 11 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company; University of Tokyo
  • Class Antineoplastics; Gene therapies; Oncolytic viruses
  • Mechanism of Action Apoprotein stimulants; Apoptosis stimulants; Gene transference; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I Prostate cancer

Most Recent Events

  • 11 Jul 2017 DS 1647 receives Orphan Drug status for Glioma in USA
  • 02 Feb 2017 Daiichi Sankyo and ActiVec agree to co-develop DS 1647 before February 2017 (Daiichi Sankyo pipeline, February 2017)
  • 06 May 2016 Adverse events data from a phase I trial in Prostate cancer presented at the 111th Annual Meeting of the American Urological Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top